2026 Global: Magnetic Resonance Imaging (Mri) Compatible Biopsy Device Market -Competitive Review (2032) report
Description
The 2026 Global: Magnetic Resonance Imaging (Mri) Compatible Biopsy Device Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Hologic, headquartered in Marlborough, Massachusetts, United States, is a leading developer of MRI-compatible breast biopsy devices and associated workflow technologies, supporting MRI-guided sampling with vacuum-assisted platforms and integrated imaging software. Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, United States, markets the Mammotome family of vacuum-assisted biopsy systems and related accessories that enable MRI-guided sampling with compatible instrumentation. Cook Medical, based in Bloomington, Indiana, United States, supplies a range of interventional biopsy devices and accessories designed for MRI-compatible operation in breast, prostate, and soft-tissue biopsy settings. Merit Medical Systems, headquartered in South Jordan, Utah, United States, offers a portfolio of biopsy needles, access devices, and vacuum-assisted systems intended for MR-guided indications and cross-modality guidance, serving the broader interventional radiology market. These devices are deployed across academic centers and medical device markets worldwide, reflecting increasing adoption of MR-guided biopsy paradigms. This trend drives ongoing device innovation worldwide.
Medtronic, headquartered in Dublin, Ireland, provides MRI-compatible interventional devices and supportive technologies that facilitate MRI-guided biopsy procedures across multiple anatomical targets, leveraging its imaging and navigation capabilities. Boston Scientific, headquartered in Marlborough, Massachusetts, United States, develops interventional biopsy tools and guidance components designed for MRI environments, spanning breast, prostate, liver, and other organ-targeted sampling applications. Stryker, headquartered in Kalamazoo, Michigan, United States, offers a range of MRI-compatible biopsy accessories and guidance devices as part of its broader interventional portfolio, enabling precise lesion targeting within MRI workflows and facilitating cross-platform integration. These manufacturers emphasize MR-conditional qualification, sterilization compatibility, and streamlined workflow interfaces to minimize procedure time and maximize tissue yield. Clinical adoption across tertiary centers and community hospitals underscores MRI biopsy's expanding role in personalized diagnosis. Advanced navigation software, lesion visualization, and integrated pathology workflows further differentiate these platforms in competitive clinical trials. Continued investment from these firms is shaping future MR-guided biopsy ecosystems worldwide today.
Koelis, headquartered in Lyon, France, develops MRI fusion biopsy platforms that integrate high-resolution MRI data with real-time ultrasound guidance to target lesions with improved accuracy, particularly in prostate cancer. MRI Interventions, Inc., based in Irvine, California, specializes in MRI-safe interventional products designed for real-time MRI-guided tissue sampling, including biopsy needles and guiding systems that support neuraxial and abdominal procedures. AngioDynamics, headquartered in Latham, New York, United States, offers interventional devices and accessories that are compatible with MRI environments, enabling targeted biopsy sampling as part of comprehensive vascular and interventional radiology workflows. These players represent a spectrum from specialized fusion platforms to configurable interventional kits, collectively expanding access to MRI-guided biopsy across academic centers and community practices. Together, they contribute to an ecosystem that emphasizes safety, sterility, MR-conditional labeling, and compatibility with existing MRI suites and navigation software. Continued investment from these firms is shaping future MR-guided biopsy ecosystems worldwide today.
Hologic, headquartered in Marlborough, Massachusetts, United States, is a leading developer of MRI-compatible breast biopsy devices and associated workflow technologies, supporting MRI-guided sampling with vacuum-assisted platforms and integrated imaging software. Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, United States, markets the Mammotome family of vacuum-assisted biopsy systems and related accessories that enable MRI-guided sampling with compatible instrumentation. Cook Medical, based in Bloomington, Indiana, United States, supplies a range of interventional biopsy devices and accessories designed for MRI-compatible operation in breast, prostate, and soft-tissue biopsy settings. Merit Medical Systems, headquartered in South Jordan, Utah, United States, offers a portfolio of biopsy needles, access devices, and vacuum-assisted systems intended for MR-guided indications and cross-modality guidance, serving the broader interventional radiology market. These devices are deployed across academic centers and medical device markets worldwide, reflecting increasing adoption of MR-guided biopsy paradigms. This trend drives ongoing device innovation worldwide.
Medtronic, headquartered in Dublin, Ireland, provides MRI-compatible interventional devices and supportive technologies that facilitate MRI-guided biopsy procedures across multiple anatomical targets, leveraging its imaging and navigation capabilities. Boston Scientific, headquartered in Marlborough, Massachusetts, United States, develops interventional biopsy tools and guidance components designed for MRI environments, spanning breast, prostate, liver, and other organ-targeted sampling applications. Stryker, headquartered in Kalamazoo, Michigan, United States, offers a range of MRI-compatible biopsy accessories and guidance devices as part of its broader interventional portfolio, enabling precise lesion targeting within MRI workflows and facilitating cross-platform integration. These manufacturers emphasize MR-conditional qualification, sterilization compatibility, and streamlined workflow interfaces to minimize procedure time and maximize tissue yield. Clinical adoption across tertiary centers and community hospitals underscores MRI biopsy's expanding role in personalized diagnosis. Advanced navigation software, lesion visualization, and integrated pathology workflows further differentiate these platforms in competitive clinical trials. Continued investment from these firms is shaping future MR-guided biopsy ecosystems worldwide today.
Koelis, headquartered in Lyon, France, develops MRI fusion biopsy platforms that integrate high-resolution MRI data with real-time ultrasound guidance to target lesions with improved accuracy, particularly in prostate cancer. MRI Interventions, Inc., based in Irvine, California, specializes in MRI-safe interventional products designed for real-time MRI-guided tissue sampling, including biopsy needles and guiding systems that support neuraxial and abdominal procedures. AngioDynamics, headquartered in Latham, New York, United States, offers interventional devices and accessories that are compatible with MRI environments, enabling targeted biopsy sampling as part of comprehensive vascular and interventional radiology workflows. These players represent a spectrum from specialized fusion platforms to configurable interventional kits, collectively expanding access to MRI-guided biopsy across academic centers and community practices. Together, they contribute to an ecosystem that emphasizes safety, sterility, MR-conditional labeling, and compatibility with existing MRI suites and navigation software. Continued investment from these firms is shaping future MR-guided biopsy ecosystems worldwide today.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
